David A.  Rosa net worth and biography

David Rosa Biography and Net Worth

Director of Biotricity
David A. Rosa is Independent Director of the Company. Mr. Dave has spent the past 22 years in a variety of positions in the medical device industry. He was appointed CEO of Sunshine Heart in October of 2009 and served as President and Chief Executive Officer through November 2015. Dave took Sunshine Heart Public on NASDAQ in 2012 and raised over $120M during his tenure. The Company achieved a number of clinical, regulatory and research and development milestones under his leadership. Prior to joining Sunshine Heart, he was President and CEO of Milksmart, Inc., a privately held company developing a unique stent-like agricultural technology that increases milking efficiencies, output and quality. From 2004-2008, Dave was Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. While at St. Jude, he developed the strategic pan for the newly formed interventional division, directed the launch of several new products and oversaw the acquisition and integration of Velocimed, a privately held company in the cardiovascular space. From 1999-2004, Dave held executive management positions at privately held A-Med Systems, Inc., an emerging medical technology company that developed ventricular assist devices (pVADs) for acute heart failure. His roles included Vice President of Marketing and Sales, Chief Operating Officer and Chief Executive Officer. From 1995- 1999, Dave served as Product Manager for Angioplasty Balloons and Director of Intravascular Ultrasound at SCIMED Life Systems, a privately held company that was engaged in the development, manufacture and marketing of medical devices to treat cardiovascular disease. SCIMED was acquired by Boston Scientific Corporation and now operates as a subsidiary of Boston Scientific. Dave holds an M.B.A. in Marketing Management from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.

How do I contact David A. Rosa?

The corporate mailing address for Rosa and other Biotricity executives is , , . Biotricity can also be reached via phone at (650) 832-1626 and via email at [email protected]. Learn More on David A. Rosa's contact information.

Has David A. Rosa been buying or selling shares of Biotricity?

David A. Rosa has not been actively trading shares of Biotricity within the last three months. Most recently, David A. Rosa sold 553 shares of the business's stock in a transaction on Monday, October 11th. The shares were sold at an average price of $18.30, for a transaction totalling $10,119.90. Learn More on David A. Rosa's trading history.

David A. Rosa Insider Trading History at Biotricity

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/11/2021Sell553$18.30$10,119.90View SEC Filing Icon  
10/7/2021Sell2,871$18.48$53,056.08View SEC Filing Icon  
9/15/2021Sell1,041$19.62$20,424.42View SEC Filing Icon  
See Full Table

David A. Rosa Buying and Selling Activity at Biotricity

This chart shows David A Rosa's buying and selling at Biotricity by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biotricity Company Overview

Biotricity logo
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
Read More

Today's Range

Now: $1.36
Low: $1.32
High: $1.38

50 Day Range

MA: $1.07
Low: $0.74
High: $1.63

2 Week Range

Now: $1.36
Low: $0.70
High: $5.10

Volume

17,392 shs

Average Volume

73,571 shs

Market Capitalization

$12.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46